Bimzelx Outperforms Skyrizi in Head-to-Head Psoriatic Arthritis Trial, Strengthening the Position of UCB’s Blockbuster Bimzelx | iPharmaCenter
Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response. This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic
European Association of Urology (EAU) 2026 Annual Meeting | News | Updates | iPharmaCenter
Johnson & Johnson Reports Encouraging Early Results for Erda‑iDRS in Intermediate‑Risk Non-Muscle Invasive Bladder Cancer Johnson & Johnson unveiled promising data from a Phase 1, open-label, multicenter clinical trial investigating its novel intravesical drug-release system containing erdafitinib (known as Erda‑iDRS, formerly TAR‑210) in patients with intermediate‑ and high‑risk non–muscle‑invasive bladder cancer (NMIBC) whose tumors carry specific FGFR (fibroblast growth fa
INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER
DEMOGRAPHICS The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments to provide health care services to citizens. The funding for healthcare in India is 3% of GDP and is continuously decreasing since (3.75% in 2013). Government spending currently accounts for 1% of GDP, and the Indian government aims to increase it to 2.5% by 2025. The infant mortality rate was reduced from 88/1,000 in 1990 to 32/1,000 in 2
FDA Grants Second Approval to Sotyktu in the US; approved for Adults with Active Psoriatic Arthritis
The U.S. Food and Drug Administration (FDA) has granted approval for Sotyktu (deucravacitinib), an oral, selective inhibitor of tyrosine kinase 2 (TYK2), for use in adult patients with active psoriatic arthritis (PsA). This marks the first approval of a TYK2 inhibitor for this condition in the United States. The decision was supported by positive outcomes from two pivotal Phase 3 clinical studies, POETYK PsA-1 and POETYK PsA-2, which evaluated the efficacy and safety of deucr
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter
Johnson & Johnson has received U.S. FDA approval for the combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy that included a proteasome inhibitor and an IMiD. The FDA reached this decision 55 days after submission, making it the third approval granted through the Commissioner’s National Priority Voucher (CNPV) pilot program. The regimen can no